Analysts Issue Forecasts for IOVA FY2027 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at Zacks Research issued their FY2027 EPS estimates for shares of Iovance Biotherapeutics in a note issued to investors on Wednesday, March 19th. Zacks Research analyst S. Ganoria anticipates that the biotechnology company will post earnings per share of $0.13 for the year. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share.

Other equities analysts have also issued reports about the company. Piper Sandler dropped their price objective on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research note on Friday, February 28th. Truist Financial cut their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Monday, March 3rd. The Goldman Sachs Group reduced their price objective on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, February 28th. Finally, Chardan Capital reduced their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.25.

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $3.54 on Friday. The company has a market capitalization of $1.16 billion, a PE ratio of -2.38 and a beta of 0.93. Iovance Biotherapeutics has a one year low of $3.42 and a one year high of $15.50. The company’s fifty day moving average price is $5.12 and its 200 day moving average price is $7.79.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The company had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Iovance Biotherapeutics by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 27,534,340 shares of the biotechnology company’s stock worth $203,754,000 after acquiring an additional 220,373 shares during the last quarter. State Street Corp grew its stake in shares of Iovance Biotherapeutics by 4.6% during the third quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company’s stock valued at $123,967,000 after purchasing an additional 576,801 shares during the last quarter. Hood River Capital Management LLC increased its holdings in shares of Iovance Biotherapeutics by 10.4% in the fourth quarter. Hood River Capital Management LLC now owns 8,991,573 shares of the biotechnology company’s stock valued at $66,538,000 after purchasing an additional 846,936 shares in the last quarter. Geode Capital Management LLC raised its position in Iovance Biotherapeutics by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 5,871,420 shares of the biotechnology company’s stock worth $43,458,000 after purchasing an additional 222,425 shares during the last quarter. Finally, Long Focus Capital Management LLC raised its position in Iovance Biotherapeutics by 13.2% in the 4th quarter. Long Focus Capital Management LLC now owns 5,132,000 shares of the biotechnology company’s stock worth $37,977,000 after purchasing an additional 600,000 shares during the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.